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1. Introduction 
The primary function of adipose tissue is storing energy in triacylglycerol (TG) form, 
neutralizing the excess of circulating lipids and saving non-adipose tissues of a fat 
overload. Under normal conditions, in the postprandial state, there is lipogenic endocrine 
system stimulation, allowing that positive energy balance can be stored as TG in adipose 
tissue, a process called lipogenesis. In contrast, the mobilization of fat in adipocytes 
occurs through the hydrolysis of TG by hormone sensitive lipase (HSL), a phenomenon 
called lipolysis. At the center of this interface - lipolysis and lipogenesis - is the insulin 
hormone, which exerts a potent inhibitory role on the HSL, allowing lower rates of 
lipolysis and hence, highest fat mass [1]. However, adipose tissue is not only a passive 
stock organ of triacylglycerol, being currently recognized as an endocrine organ with 
multiple functions [1, 2]. Produces several biologically active substances called 
adipokines, among them tumor necrosis factor- (TNF-), monocyte chemoattractant 
protein 1 (MCP-1), interleukin-6 (IL-6), leptin, resistin and adiponectin. These substances 
actively participate in, among others, body energy regulation, mainly, by endocrine, 
paracrine and autocrine signals, which allow the adipocyte play a metabolic role in other 
tissues [3-5].  
However, in obesity there is an imbalance in adipokines production, a fact which, together 
with the inability to store fat in the adipocytes, results in a process of adipose tissue 
dysfunction [6], a known risk factor for developing obesity-associated metabolic disorders 
[1, 2, 6]. This fact occurs because the adipocytes (hypertrophic and hyperactive) initiates the 
production of adipokines and chemotactic factors (such as MCP-1), which attract 
macrophages into the adipose tissue [7]. Consequently there is a synergistic interaction on 
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proinflammatory adipokines production - mainly TNF-α - and antagonistic on adiponectin. 
These substances lead to insulin resistance, reducing the lipogenic action of insulin in 
adipocytes, which results in higher rates of lipolysis in the adipose tissue [8, 9]. On the other 
hand, calorie restriction affects the regulation of adipose tissue gene expression, normalizing 
the adipokines changes observed in obesity [10]. 
 
Figure 1. Adapted from van Kruijsdijk et al, 2009 [6]. In obesity the hypertrophic and hyperactive 
adipocytes initiate the production of MCP-1, which attract macrophages into the adipose tissue, 
increasing proinflammatory adipokines production (mainly TNF-α) and decreasing adiponectin 
production, leading to insulin resistance and inflammation. The weight loss process revert this 
alterations, improving insulin resistance and inflammation. FFA: fatty free acids; PAI1: Plasminogen 
activator inhibitor 1; TNFα: tumor necrosis factor-α; MCP1: monocyte chemoattractant protein 1; IL6: 
interleukin 6. 
In this chapter will be revised about the influence of thyroid hormones on adipokines in 
obesity and weight loss. Also will be discussed the physiological role of adipokines as well 
as the effect of obesity and weight loss on the adipokines. 
2. Adipokines physiological role  
The adipose tissue is considered an endocrine organ and shows great dynamism. Since 1940 
there is a hypothesis that adipose tissue has signals to communicate with other tissues [11], 
but only later was shown that this tissue is able to synthesize and secrete a large number of 
protein factors (which also act as cytokines) collectively called adipokines. These 
adipokines, in most part, are related, directly or indirectly, in processes involving 
atherosclerosis, hypertension, insulin resistance (IR) and type 2 diabetes (DM2), 
dyslipidemia, ie, represent the link between adiposity, metabolic syndrome and 
cardiovascular diseases [12-15]. Among these is Leptin, Resistin, Adiponectin, and others 
such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), plasminogen activator 
inhibitor-1 (PAI-1), acylation stimulating protein (ASP) and factors involved in the renin-
angiotensin system (RAS). 
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2.1. Leptin 
With its gene identified in 1994 [16] leptin is the adipokine most studied and thenceforth it 
has been identified more than 30 biochemical products secreted by adipocytes. Leptin is a 
peptidic hormone with 167 amino acids and 16kDa of molecular weight and synthesized 
from the “ob” gene in adipocytes, being more common in subcutaneous adipose tissue than 
in visceral fat [17]. Besides to be considered an important lipostate, or energy balance 
regulator according to body fat mass in long-term [18, 19] has been implicated in the 
regulation of immune, respiratory and reproductive systems [20]. The term Leptin comes 
from Greek "leptos" which means "thin" due to the fact that this protein lead to increased 
energy expenditure and act on satiety signals in hypothalamus, reducing caloric intake [21]. 
The expression and circulating leptin levels are controlled by a number of factors that may 
increase its secretion (insulin, glucocorticoids, TNF-α, estrogens, thyroid hormone and 
CCAAT/enhancer-binding protein-alpha) or decrease (Beta3-adrenergic activity, androgens , 
free fatty acids, GH, and peroxisome proliferator-activated receptor-gamma agonists) 
depending on the physiological assembly expressed by the body, especially on satiety and 
energy intake [22]. 
When circulating this adipokine reaches various body tissues as pancreas, increasing insulin 
secretion; liver, causing a satiety sensation by the increase in glucose production and 
increasing energy expenditure; hypothalamus, increasing stimulation of hypothalamic-
pituitary-adrenal axis, and decreasing the stimulus of hypothalamic-pituitary-thyroid and 
hypothalamic-pituitary-gonadal axis; muscle tissue, increasing glucose uptake and 
metabolism [23]. 
Many of the effects of leptin result from their actions on the central nervous system, 
particularly in the hypothalamus, which acts in satiety and appetite regulation. Reaching 
these tissues after crossing the blood-brain barrier, leptin acts in the arcuate nucleus where 
there is a large concentration of leptin receptors, when binding to reduce the action of 
neurons that use neuropeptide Y (NPY) signaling and agouti-related protein (ARGP). NPY 
is a peptide of 36 amino acids, synthesized mainly in the arcuate nucleus, which projects to 
the paraventricular nucleus, ventromedial, perifornical and lateral, also involved in energy 
balance regulation. It is the most potent orexigenic. The ARGP also synthesized in the 
arcuate nucleus, also is projected to paratentricular nucleus, ventromedial and lateral, acting 
as a melanocortin system analogue on receptors MC-3 and MC-4, stimulating food intake. 
Leptin acts by decreasing the activity of these orexigenics signals, inhibiting food intake and 
increasing energy expenditure by activating the sympathetic nervous system [24, 25]. Also 
in the hypothalamus, leptin activates neurons pro-opiomelanocortin (POMC) producing 
alpha-melanocyte stimulating hormone (alpha-MHS). All substances expressed in this 
system are anorexigenics, ie, act on reducing food intake [14]. This product acts on 
malanocortin-4 receptors and also on neurons that express cocaine and amphetamine-
regulated transcript (CART). POMC/CART neurones also have projections to the lateral 
hypothalamus and paraventricular nucleus, with a reciprocal innervation of these nuclei to 
the arcuate nucleus. Both alpha-MSH and CART are potent anorexigenic agents. The 
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nucleus tractus solitarius (NTS) participates in the satiety control, involved in the end of 
food intake process. Afferent inputs related satiety signals include neurological vagus nerve 
and sympathetic system associated with chemical signals such as endocrine factors of gut 
cholecystokinin. There are many interconnections between hypothalamic nuclei including 
the paraventricular nucleus and the NTS (Figure 2). 
 
Figure 2. Food intake regulation by leptin at arcuate nucleus level. NPY: Neuropeptide Y; AGRP: 
Agouti-related protein; POMC: Pro-opiomelanocortin; CART: Cocaine and amphetamine-regulated 
transcript. 
Among the actions taken by other hypothalamic nuclei in relation to energy homeostasis, 
can be highlight the ventromedial nucleus as a satiety center, lateral hypothalamus as the 
center of hunger and paraventricular nucleus on increased energy expenditure effects, as 
production of corticotropin releasing hormone and thyrotropin releasing hormone, 
activators the sympathetic nervous system. In perifornical nucleus, there is production of 
peptides termed orexins A and B, which act in the ventromedial nucleus and inhibits satiety 
and increase food intake. These areas receive nucleus axons of neurons in the arcuate 
nucleus, POMC/CART and NPY/ARGP, being considered as secondary action areas of 
leptin (downstream) [14, 26]. The leptin role in the CNS as a regulator is thus triggering 
mechanism (cascading effect), in order to stimulate or inhibit substances that act directly or 
indirectly in the hypothalamic areas involved in energy balance control. 
In addition to their central effects, leptin also interacts with numerous peripheral tissues. 
Essentially, there are two major isoforms of leptin receptor, a long isoform which is required 
for full stimulation of the janus kinase-signal transducers and activators of transcription 
(JAK-STAT) pathway, and the short isoforms which result in the activation of JAK2 but not 
STAT. In skeletal muscle, for example, there are the two isoforms but the expression of short 
isoform is greater than the long one, making the leptin signalization in skeletal muscle 
activate various kinases including PI3-kinase, Akt (or PKB), PKC, MAP kinase kinase and 
Jun ERK [27, 28]. 
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In the immune system the leptin receptor are expressed in hematopoietic cells, where leptin 
produced by adipocytes stimulates the normal growth of myeloid and erythroid [14]. In 
addition, leptin synergistically acts with other cytokines by increasing the proliferation of 
leukocytes, specifically T4 cells. 
Leptin effects on reproduction are varied and the target organs range of hypothalamus, 
ovary and endometrial. In the hypothalamic-pituitary axis there is a stimulatory effect [29]. 
Its levels have a circadian and ultradian cycle, and these variations are associated with 
varying levels of luteinizing hormone (LH) and estradiol, informing to the brain about the 
critical fat stores necessary for secretion of luteinizing releasing hormone and activation of 
hypothalamic-pituitary-gonadal axis [30]. The amount of leptin released in the brain is 
greater in women than in men, suggesting that women may be more resistant to the leptin 
action and require higher levels to achieve an appropriate response [31]. It is known that 
leptin, in ovaries, may affect the menstrual cycle by a direct inhibitory effect on the follicles 
development [29]. Leptin may still have an important role in the early stages of cleavage and 
embryonic development [32], in the fetal growth regulation and development, 
hematopoiesis and angiogenesis, as leptin receptors were found in syncytiotrophoblast, 
suggesting that leptin may play an important role in fetal endocrine function of feto-
placental unit [33]. In addition, leptin may play a central role in other target organs for 
reproduction, such as endometrial and mammary gland, influencing important functions 
including lactation and prevention of misbirth [34]. 
In the respiratory system leptin acts as a growth factor in the lung and as a modulator in the 
mechanisms of breathing central control. Leptin levels are elevated in patients with sleep 
apnea, independent of body fat, being associated with leptin resistance [14]. 
For hypothalamic-pituitary-thyroid axis leptin acts on the expression of thyrotropin-
releasing hormone (TRH). Mice in vitro and in vivo study has demonstrated that leptin 
stimulates neurons directly in the paraventricular nucleus, which express TRH, increasing 
proTRH expression [35]. During fasting, the prohormone convertases 1 and 2 (PC1 and PC2) 
are decreased and leptin showed to restore PC1 and PC2 to pre-fasting levels [36]. Studies in 
rodents have shown that calorie restriction rapidly suppresses TRH expression in the 
paraventricular nucleus, leading to decreased thyroxine (T4) and triiodothyronine (T3) levels 
[37], and leptin can reverse these changes [38]. 
Both partial and complete deficiency of leptin is associated with hypothyroidism. Ob/ob 
mice exhibit hypothyroidism at birth [39] and normal mice have decreased T4 levels during 
fasting [38]. Individuals with congenital leptin deficiency have a disorganized TSH 
secretion, suggesting that leptin may regulate the pulsatile characteristics of TSH and the 
circadian cycle [40]. In women with hypothalamic amenorrhea leptin treatment significantly 
increased free T3 and free T4, however did not affect TSH levels [41]. The lack of significant 
changes in TSH levels in many studies may be due to pulsatile nature of this hormone, but 
leptin can directly stimulate the T4 release from the thyroid gland and/or increase TSH 
bioactivity [42, 43]. 
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2.2. Resistin 
Resistin is a polypeptide at approximately 12kDa and belongs to proteins family with 
cysteine-rich C-terminal domain call resistin-like molecules, which are identical to those 
found in inflammatory zone family, giving to resistin the alias FIZZ3 [44]. Its expression is 
15 fold higher in visceral adipose tissue when compared to subcutaneous adipose tissue, in 
rodents [44], but it is also expressed in human macrophages [45]. Its name is due to the 
resistin presents a significant role in obesity-associated insulin resistance [46] and its 
molecular structure is very similar to adiponectin. Resistin production increases with food 
intake and obesity, and decreases in the presence of PPAR-gamma ligands [47]. 
Resistin promotes insulin resistance by increasing hepatic gluconeogenesis, and presenting 
rapid effect on this tissue [47]. Other in vivo study also found effects of administration and 
neutralization of resistin on glucose tolerance in skeletal muscle and adipose tissue, 
indicating resistin action also in these tissues by negative modulation of insulin signaling on 
glucose uptake [46]. 
Regarding the specific body fat deposits, resistin expressions 2-3 fold higher is found in 
visceral adipose tissue, followed by subcutaneous, abdominal and gluteal-femoral 
subcutaneous. Its expression is 3 fold higher in preadipocytes compared with mature 
adipocytes, also functioning as a potential regulator of adipogenesis [48]. 
Resistin deficient mice have weight and fat mass similar to wild-type mice, even when 
high-fat fed. However, resistin deficient mice significantly improved fasting glucose levels 
in control diet and improved glucose tolerance in high-fat diet. Insulin sensitivity is 
unaffected. The improvement in glucose homeostasis in resistin deficient mice is 
associated with decreased hepatic gluconeogenesis. Whereas these data support a resistin 
role in glucose homeostasis during fasting in rodents, a similar role in humans remains to 
be determined [3]. 
2.3. Adiponectin 
Adiponectin, also known as ACRP 30 (adipocyte complement related protein of 30kDa), 
apM1 (adipose most abundant gene transcript 1), AdipQ or GBP28 (gelatin binding protein 
of 28 kDa) [49-52], is a protein exclusively expressed in differentiated adipocytes and 
circulates in high levels in the blood [53], presenting greater expression in subcutaneous 
adipose tissue than in visceral adipose tissue [54]. Unlike other factors secreted by adipose 
tissue, adiponectin acts as a protective factor for cardiovascular disease and increases insulin 
sensitivity. It is an approximately 30 kDa polypeptide that shows high homology with 
collagen VIII and X, and complement component C1q. A proteolytic cleavage product 
containing the globular domain of adiponectin circulate in physiologically significant levels 
and has biological activity [53]. 
Except for cases of severe malnutrition [55] and in neonates [56], there is a strong negative 
correlation between plasma adiponectin and fat mass [52]. 
 
Obesity and Weight Loss: The Influence of Thyroid Hormone on Adipokines 219 
Were identified two adiponectin receptors isoforms (Adipo-R1 and -R2) [57]. This receptors 
present seven transmembrane domains but are functionally different of receptors coupled to 
G protein. AdipoR1 is expressed mainly in muscle tissue and has high affinity for globular 
adiponectin, and low affinity for full-length adiponectin. AdipoR2 has high expression in 
liver and has intermediate affinity for both isoforms of circulating adiponectin. Thus, it is 
noted that the biological effects of adiponectin depends not only on circulating levels or the 
properties of each isoform but also receptor subtype and its expression in each tissue [3]. 
Adiponectin anti-inflammatory and anti-atherogenic actions occurs through decreased 
expression of adhesion molecule-1 (via reduced expression of TNF-alpha activity and 
resistin); decreased macrophage chemotaxis to fat cells formation; and inhibition of 
inflammatory signaling in endothelial tissue [58]. It increases insulin sensitivity via 
increased fatty acid oxidation and glucose uptake and utilization in skeletal muscle and 
adipose tissue; reduction of hepatic glucose release, leading to better control of glucose 
serum levels, free fatty acids and triglycerides [59]. In rat adipocytes, in vitro, the 60% 
reduction in adiponectin expression increased significantly insulin resistance. The presence 
of nucleotide polymorphisms in adiponectin caused by genetic or environmental factors 
(diet rich in fat, for example), can be a determining factor in reducing their insulin 
sensitizing action [60]. 
In the liver, adiponectin increases insulin sensitivity by reducing nonesterified fatty acids 
uptake, increasing fatty acid oxidation and decreasing glucose output. In muscle, 
adiponectin stimulates glucose metabolism and fatty acid oxidation. In the endothelium, it 
inhibits monocyte adherence by reducing adhesion molecules; inhibits macrophages 
transformation and reduces migrating smooth muscle cells proliferation in response to 
growth factors. Adiponectin also increases nitric oxide production by endothelial cells and 
stimulates angiogenesis. Taken together, these effects suggest that adiponectin is the only 
adipokine that present antidiabetic, anti-inflammatory and anti-atherogenic effects [3]. 
2.4. Others adipokines 
Tumor Necrose Factor - alpha (TNF-α) – TNF-α is a cytokine expressed by adipocytes and 
stromovascular cells, with higher expression in subcutaneous adipose tissue compared to 
visceral adipose tissue, acting directly on adipocytes, promoting apoptosis induction, 
lipogenesis inhibition, by inhibiting lipoprotein lipase (LLP), GLUT-4 and the acetyl CoA 
synthetase expressions, as well as increased lipolysis, therefore exerting an important 
regulatory role in fat accumulation in adipose tissue [61, 62]. TNF-α is a transmembrane 
protein of 26 kDa, which, after being cleaved generates a portion of 17-kDa, which is 
biologically active and exerts its effects through TNF- receptor type I and II. It is a cytokine 
initially described as an endotoxin-induced factor causing necrosis in tumors. The ability of 
TNF to induce cachexia in vivo led to an extensive evaluation of its role in energy 
homeostasis [3]. TNF-α alters gene expression of metabolically important tissues such as 
adipose tissue and liver [63] and impairs the insulin signaling by activation of serine kinases 
that increase the insulin receptor substrate-1 and -2 phosphorylation, increasing its 
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degradation [64]. Both TNF-α and triiodothyronine are involved in the tissue homeostasis 
maintenance of the anterior pituitary gland, however, triiodothyronine inhibit the signaling 
cascade that TNF-α promotes on this tissue in signaling pathways affecting MAPK p38 and 
nuclear factor kappaB [65]. 
Interleukin-6 (IL-6) – IL-6 is also a cytokine with pro-inflammatory effect in acute responses 
and action on carbohydrates and lipids metabolism [66, 67]. IL-6 circulates in glycosylated 
form ranging from 22 to 27 kDa. Its receptor (IL-6R) is homologous to the leptin receptor 
and exists in two isoforms, a membrane-bound and soluble. The infusion of IL-6 near 
physiological doses, in healthy humans, increase lipolysis independently of catecholamines, 
glucagon and insulin modulation [68], indicating IL-6 as an important factor in lipid 
metabolism. As TNF-α, it inhibits the LLP and increases free fatty acids and glycerol release. 
Furthermore, the increased expression may be related to leptin suppression and stimulation 
of C-reactive protein production, as well as in reducing IRS-1 and GLUT-4 expression in the 
liver and muscle [66]. IL-6 is secreted by adipocytes and macrophages, which are 
responsible for 30% of its secretion [67]. Catecholamines can stimulate IL-6 expression via 
β2-and β3-adrenoceptors in adipose tissue, when in high concentrations [69]. The IL-6 
central administration increases energy expenditure and decreases body fat in rodents. Also, 
transgenic mice with IL-6 overexpressed showed generalized growth deficiency and 
reduced body mass, however, IL-6 deficient mice develop obesity and metabolic 
abnormalities, suggesting that IL-6 may prevent, rather than cause these conditions [70]. 
Monocyte chemotactic protein-1 (MCP-1) – MCP-1 is a chemokine and a member of the small 
inducible cytokine family, which plays a role in the recruitment of monocytes and T 
lymphocytes to sites of injury and infection. Its main receptor is the chemokine CC motif 
receptor (CCR) 2 that is expressed in various cell types including adipocytes, skeletal muscle 
cells and macrophages. MCP-1 was first described as a secretory product of monocytes and 
endothelial cells with a role in atherosclerosis. MCP-1, acting through its receptor CCR2, is 
now thought to play a central role in the recruitment of monocytes to atherosclerotic lesions 
and in the development of intimal hyperplasia after arterial injury. Owing to their crucial 
roles in monocyte recruitment in vascular and nonvascular diseases, MCP-1 and CCR2 have 
become important therapeutic targets in cardiovascular research. Furthermore, MCP-1 plays 
a role in inflammation in insulin-responsive tissues. As for skeletal muscle, MCP-1 is 
increased during myopathies and can be induced by interferon-gamma. Recently, MCP-1 
has been attributed an additional role in the pathophysiology of obesity [71]. 
Plasminogen activator inhibitor (PAI)-1 – Adipocytes can secrete many proteins in hemostasis 
and fibrinolytic system as PAI-1 [72]. PAI-1 is a member of the serine protease inhibitor 
family and is the primary inhibitor of fibrinolysis by inactivating urokinase-type and tissue-
type plasminogen activator. PAI-1 has also been implicated in a variety of other biological 
processes including angiogenesis and atherogenesis. PAI-1 is expressed by many cell types 
within adipose tissue including adipocytes [3]. PAI-1 expression and secretion are greater in 
visceral adipose tissue relative to subcutaneous adipose tissue [54]. PAI-1 promotes thrombi 
formation and unstable atherogenic plaque rupture, and change the fibrinolytic balance by 
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inhibition of plasmin production, contributing to vascular architecture remodeling and 
atherosclerotic process [66, 73].  
Adipsin and acylation stimulating protein (ASP) – Also secreted by adipose tissue it has an 
important effect on lipogenesis [59]. APS inhibits the lipolysis by inhibition of hormone 
sensitive lipase (HSL), and stimulating lipogenesis by increasing GLUT4 translocation from 
cytosol to membrane; increases glycerol-3-phosphate production and increases 
diacylglycerol acyltransferase activity, an catalyst enzyme in triglycerides synthesis [74]. 
Thus affects both the glucose and the lipid metabolism.  
Proteins of the renin angiotensin system (RAS) – Pathogenic models have been proposed to 
explain the association between adiposity and the renin angiotensin system [75]. This seems 
to be related to fat accumulation in adipose tissue, as well as its involvement in 
inflammatory and atherogenic process. Adipose tissue secretes many proteins related to the 
RAS as renin, angiotensinogen (AGT), angiotensin I, angiotensin II, angiotensin type I 
receptors (AT1) and type 2 (AT2) angiotensin-converting enzyme (ACE), and other 
proteases capable of producing angiotensin II (chymase, cathepsins D and G) [76, 77]. The 
angiotensin I receptor is secretion inductor of series 2 prostaglandins which participates in 
preadipocytes cell differentiation, and the angiotensin II stimulates adipocytes 
differentiation and lipogenesis in time of angiotensin I to II conversion, indicating their 
involvement in the accumulation of fat mass process [78].  
3. Adipokines and thyroid hormones 
The thyroid gland mainly produces the thyroid hormones T3 and T4. However, also 
produces small amounts of other iodothyronines as reverse T3 and 3,5-diiodo-L-thyronine. 
This gland is part of hypothalamic-pituitary-thyroid axis. Thyroid hormones secretion is 
regulated by the classical mechanism of negative feedback; briefly, thyroid releasing 
hormone (TRH), produced predominantly by neurons of the paraventricular nucleus in 
the hypothalamus, stimulates the release of thyroid stimulating hormone (TSH) in 
pituitary and this in turn, stimulates the synthesis and release of thyroid hormones. The 
increase in thyroid hormones serum concentrations inhibit the production of both TRH 
and TSH, leading to decreased thyroid function. The subsequent decrease in thyroid 
hormones serum levels, in turn, stimulates TRH and TSH, again increasing the 
concentration of hormones [79]. Thyroid hormones act in the body through the coupling 
to its receptor  (TR) and  (TR). The thyroid hormone receptors (TRs), members of the 
superfamily of nuclear receptors interact with a specific DNA sequence, called responsive 
element in the promoter region of target gene and regulates gene transcription [80]. 
Generally, TRs are repressors in the absence of binding T3 and transcriptional activators in 
its presence [81]. 
Although the thyroid hormones are essential for the survival [37], thyroid function disorder 
leads to changes in metabolic parameters, for example, thyroid hormone excess is associated 
with weight loss and reduced muscle and fat mass [82] , showing that thyroid hormones 
play a central role in regulating the adipose tissue metabolism [83]. Furthermore, Viguerie et 
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al. [84] showed by microarray that 19 genes of human white adipose tissue are regulated by 
thyroid hormone. These modulated genes give rise to proteins involved in transduction 
signal, lipid metabolism, apoptosis and inflammatory responses. The thyroid hormones 
inhibit proliferation and stimulate differentiation of adipocytes [85], regulate lipid 
metabolism by upregulation lipolytic enzymes expression, increase oxygen consumption 
and modulate tissue sensitivity to other hormones [84]. 
Since thyroid hormones affect adipose tissue metabolism, it is interesting to evaluate the 
relationship between thyroid hormones and adipokines in obese and weight loss, the focus 
of discussion in next sections. 
4. Thyroid hormone effect on adipokines in obesity 
4.1. Leptin 
A potential interaction between leptin and thyroid hormones has been suggested since both 
hormones are associated with body weight and energy expenditure regulation. 
Leptin deficiency leads to severe obesity, however, in humans it’s usually find high levels of 
leptin associated with leptin-resistance state [86-91]. Although thyroid function is usually 
normal in obese subjects, many studies have demonstrated that TSH levels are slightly 
increased in obese subjects [92-94]. Several studies have suggested that leptin influences 
TSH release, suggesting a regulatory role by leptin on thyroid axis at least in some 
conditions [35, 40, 95-101]. Thyroid hormones regulate the expression of several genes in 
human adipocyte [84], however, the role of thyroid hormones in leptin modulation remains 
controversial (Figure 3).   
 
Figure 3. Adapted from Feldt-Rasmussem, 2007. Leptin can act on TRH or can directly influence T4 – 
T3 conversion, showing a regulatory role on thyroid axis. Despite contradictory data, thyroid 
hormone also regulates leptin levels increasing or decreasing depending on condition. TRH: thyroid 
release hormone; TSH: thyroid stimulating hormone; UCP3: uncoupling protein 3; T4: thyroxine; T3: 
triiodothyronine. 
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Studies with rodents indicate that thyroid hormones exert a negative influence on serum 
leptin concentrations [102-105]. Syed et al. [106] also found similar results, but report that 
thyroid hormones influence leptin levels indirectly through the regulation of fat mass. Wang 
et al. [107] reported that although leptin and thyroid hormones might affect the same 
pathways to regulate energy metabolism, the leptin effects on metabolism are not 
dependent upon the presence of thyroid hormones. In agreement, Luvizotto et al. [108] 
reported that T3 administration in obese rats promotes weight loss and diminishes serum 
levels and gene expression of leptin and other adipokines. Contrary to these results, Yoshida 
et al. [109] founds increased leptin mRNA levels in 3T3-L1 cell cultures treated with T3 at 
physiological and supraphysiological doses.  
Obese human subjects have high serum leptin levels as leptin concentrations are directly 
proportional to body fat mass, more specifically to adipocyte volume [110, 111]. Regarding 
to thyroid hormones, there is indications that human obesity is usually associated with 
increased TSH and T3 levels [92, 112]. As in rats, studies with humans reached to 
controversial results about the effect of thyroid hormones over leptin concentrations. In fact, 
human studies present more difficulties in terms of controlling variables as patient 
characteristics, treatments and method for measuring leptin levels and body composition. In 
hypothyroid subjects serum leptin was found to be increased [83, 113], decreased [114, 115] 
or unchanged [116, 117] when compared with euthyroid subjects. The same controversial 
results are found in studies with hyperthyroid subjects [83, 113, 115-118]. 
These conflicting results might be explained by the existence of many factors influencing 
leptin levels and thyroid hormones, and more studies are needed to fully understand the 
relationship between leptin and thyroid hormones. 
4.2. Resistin 
Resistin is strongly related to insulin resistance, showing increased resistin concentrations in 
obese and diabetic animals [46], and additionally it has been associated with inflammatory 
condition [119]. There is evidence that the hyperlipidic diet-induced obesity as well as leptin 
gene mutations are associated with high resistin circulating levels [120]. Resistin 
administered intraperitoneally increases plasma glucose and induces a hepatic insulin 
resistance. Other studies involving administration of resistin-recombinant promoted insulin 
resistance and reduced glucose transport stimulated by insulin, whereas administration of 
anti-resistin antibodies produced the opposite effect in rats [46]. Moreover, anti-resistin 
antibodies decrease blood glucose levels and improve the insulin sensitivity in obese rats 
[121, 122]. In mice with diet-induced obesity, immunoneutralization of resistin resulted in a 
20% drop in blood glucose and improved insulin sensitivity as measured by insulin 
tolerance testing [46]. 
Resistin in humans is primarily produced in peripheral blood monocytes and its levels 
correlate with IL-6 concentrations [120], the question of its inflammatory role has been 
raised  [123, 124], however the physiological role of resistin is far from clear and its role in 
obesity and insulin resistance and/or diabetes is controversial. Janke et al. [121] describes in 
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adipose tissue of obese individuals, although this adipokine has been identified, there was 
no correlation between resistin gene expression and their body weight, adiposity and 
insulin resistance. In contrast, high resistin levels are related to obesity and insulin 
resistance [46], and since body mass index has a possible association with thyroid hormones 
during periods of weight gain [125], could be establish a relationship between thyroid 
hormones and resistin in obesity.  
Thyroid hormones appear to regulate resistin, at least in rats, however, in humans, studies 
on resistin levels and thyroid status have produced conflicting results. Some studies report 
that patients with hyperthyroidism have elevated resistin concentrations when compared 
with euthyroid control subjects [126]. Normalization of circulating thyroid hormones was 
accompanied by a significant decrease in resistin concentrations [126]. Others showed that 
hyperthyroid patients exhibit a significant decrease in resistin levels compared with 
euthyroid individuals. Normalization of circulating thyroid hormones levels was not 
accompanied by any significant change in resistin levels [127]. After adjusting the weight by 
the body mass index, the resistin levels of hyperthyroid patients were similar to euthyroid 
individuals [128]. 
Azza et al. [129] in their study with hypothyroid rats found an increase in body mass index 
without changes in resistin levels. On the other hand, Nogueiras et al. [130], found that 
adipose tissue resistin mRNA levels were increased in hypothyroid rats and decreased, to 
almost undetectable levels, in hyperthyroid rats. These data may help to explain previous 
findings showing a marked improvement in insulin resistance observed in obese rats after 
treatment with exogenous thyroid hormones [106]. Luvizotto et al. [108] reported that 
administration of T3 supraphysiological doses decreased resistin serum levels and ressitin 
mRNA gene expression in adipose tissue in obese rats. 
Data on the effect of thyroid hormones on resistin are scarce and controversial, so more 
studies are needed to elucidate the exact mechanism by which thyroid hormones may 
influence resistin levels. 
4.3. Adiponectin 
The main target tissue and the precise mechanism of adiponectin action are not fully 
understood. The adiponectin activity is probably regulated at several levels, including gene 
expression, post-transcriptional modifications, oligomeric complexes formation, and 
proteolytic cleavage into smaller and perhaps more active fragments [131]. Some 
experimental models suggest that reduced adiponectin expression is associated with obesity 
and insulin resistance. Adiponectin expression may be activated during adipogenesis, but 
the feedback inhibition on its production may be involved in obesity development. It has 
been shown that adipogenic genes expression was suppressed during obesity and diabetes 
development in mice [132]. A negative correlation between obesity and circulating 
adiponectin has been well accepted. 
Studies of a possible relationship between adiponectin and lipid metabolism changes 
associated with thyroid dysfunction are scarce. Hyperthyroid patients showed an increase 
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in body weight, body mass index and cholesterol serum levels after controlling for 
thyrotoxicosis. The lack of correlation between these parameters and serum adiponectin 
suggests that changes in body composition and lipid profile observed in hyperthyroidism 
are independent of adiponectin. In contrast, patients with hypothyroidism showed 
elevated cholesterol and triglycerides levels when compared to normal subjects. Thyroid 
function control was followed by a significant decrease in serum cholesterol and 
triglyceride concentrations. However no relationship between adiponectin and lipid 
profile before and after therapy was evidenced. Furthermore, after adjusting adiponectin 
levels for body mass index, no significant change was observed in patients with hyper- 
and hypothyroidism, suggesting that thyroid hormones play a small role in adiponectin 
levels modulation [128]. 
An experimental study of rats with hyperthyroidism showed an important rise in serum 
adiponectin [133]. However, in contrast, Cabanelas et al. [134] show reduced adiponectin 
gene expression in inguinal explants of normal rats. Confirming this data Luvizotto et. al. 
[108] demonstrate that obese animals had decreased adiponectin serum levels when 
compared to control animals; and the administration of T3, interestingly, even diminishing 
the body fat mass, presented lower levels of adiponectin; showing that supraphysiological 
T3 doses alter adiponectin expression in obesity, suggesting that T3 may cause undesirable 
effects on adipose tissue. 
4.4. Others adipokines 
TNF-α - Fruhbeck et al. [135] in their investigations revealed a narrow molecular link 
between TNF-α and obesity, verifying that TNF-α expression is increased in obesity, which 
in turn decreased insulin sensitivity, the same way of resistin. High-fat fed rodents showed 
significantly increased TNF-α expression and alteration in insulin signaling pathway in 
vivo [136]. Anti-TNF-α antibodies improves insulin sensitivity in obese rats, whereas TNF-
α deficient animals, even when subjected to high-fat diet, present themselves "protected" 
from obesity development and insulin resistance. TNF-α is a cytokine that may be 
involved in autoimmune thyroid disease development [137, 138]. Jiskra & Telicka [138] 
examined the relationship between thyroid function and cytokines, using patients with 
Graves' disease (characterized by hyperthyroidism), and patients with Hashimoto 
thyroiditis (disease characterized by hypothyroidism). The cytokine profile was assessed 
and patients with Hashimoto's thyroiditis present body mass index above the ideal level 
and TNF-α serum levels smaller than in patients with Graves' disease, who had body 
mass index within normal limits. Díez et al. [139] show that patients with 
hyperthyroidism before treatment present TNF-α serum levels higher than in control 
group, but hyperthyroidism treatment was accompanied by normalization of TNF-α 
levels. However TNF-α reduction was not observed in patients with hypothyroidism who 
have had the thyroid function normalized, despite a positive correlation between the 
TNF-α post-treatment levels and weight loss.  
IL-6 - IL-6 levels are increased in obesity [140], and is also a marker of insulin resistance [141, 
142]. According Nonogaki et al [143], metabolic impact produced by increased expression of 
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IL-6 in the body fat deposits can be very importante in the obesity pathogenesis. The 
increase in IL-6 plasmatic could stimulate the hepatic synthesis of triacylglycerol, 
contributing to hypertriglyceridemia associated with visceral obesity. Data on relationship 
of thyroid hormones and IL-6 in obesity are scarce, but the association between reduction of 
T3 circulating levels and increasing pro-inflammatory cytokines, particularly IL-6, is 
described in the literature in both animals’ models and human studies - septic patients 
and in patients with systemic inflammatory response [144, 145]. The acute subcutaneous 
administration of IL-6 (5 mg) in rats was associated with decrease in T4,T3 and TSH serum 
concentrations, while the T4/T3 ratio decreased, suggesting that T4 deiodination was not 
affected [144]. Changes in serum thyroid hormone concentrations could effectively be 
ascribed to IL-6, since they could be prevented by IL-6 preincubation with its neutralizing 
antibody [144]. The continuous IL-6 intraperitoneal infusion (15 mg/day for 7 consecutive 
days) in rats was associated with a transient decrease in serum T4 and TSH, although less 
than that caused by IL-1 [145]. In latter study, pro-TRH mRNA hypothalamic and 
pituitary TSH-b mRNA were unaffected by IL-6, suggesting that the effects of IL-6 on TSH 
might not necessarily be associated with a decreased synthesis of thyrotropin [145]. On 
the other hand, the observation that the intracerebroventricular IL-6 administration to rats 
was followed by a decrease in serum TSH and an increase in serum adrenocorticotropin 
(ACTH) concentrations, while these changes could be reproduced in hemipituitaries only 
for ACTH, but not for TSH, suggested that the action of IL-6 on TSH might be exerted 
predominantly at the hypothalamic levels [146]. Increased concentrations of cytokines, 
especially IL-6, are often found in nonthyroidal illness patients and correlate with changes 
in thyroid hormone concentrations [144]. 
MCP-1 - Expression in adipose tissue and plasma MCP-1 levels have been found to 
correlate positively with the degree of obesity [7, 147-149]. Elevated circulating levels of 
MCP-1 as well as MCP-1 mRNA have been reported in obese mice [149, 150]. The 
possibility that MCP-1 formation in adipose tissue is due to macrophage infiltration must 
be considered since obesity is associated with various degrees of macrophage 
accumulation in adipose tissue [7, 147]. No data on this adipokines and thyroid hormone 
have been published. 
PAI-1 - Adipose tissue PAI-1 gene expression and serum concentration have been reported 
in several pathological conditions, such as obesity, hyperinsulinemia, and hyperglycemia 
[151, 152]. The thyroid hormones T4 and T3 also have cardiovascular effects, probably 
through the regulation of circulating clotting proteins and fibrinolytic activity [153]; 
however, the mechanisms leading to cardiovascular and thromboembolytic diseases in 
thyroid dysfunction are controversial. Some reports have described an increase in serum 
PAI-1 concentration in hyperthyroidism, whereas others did not detect any differences [154, 
155]. Biz, et al. [158] determined the effects of in vivo treatment of rats with the thyroid 
hormone T4 on gene expression and the serum concentration of PAI-1. Additionally, the 
effects of T3 and T4 on PAI-1 gene expression in 3T3-L1 adipocytes were also evaluated. The 
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results demonstrated that adipocytes present different responses to thyroid hormones when 
considering in vivo and in vitro experiments. Other investigations have also demonstrated 
different in vivo and in vitro responses. The diverse in vivo and in vitro effects of thyroid 
hormones on PAI-1 gene expression regulation are not related to the inhibitory effect of T4 
on thyroid-stimulating hormone (TSH) secretion, since the literature has not shown any 
relationship between TSH and PAI-1 serum concentration [157]. However, it could be 
suggested that the lower amount of thyroid hormone receptors and deiodinase present in 
white adipose tissue than in brain, liver, brown adipose tissue, and kidney may be involved 
in this process. In addition, the low blood flow in white adipose tissue in comparison to 
other tissue types [158] could contribute to hormone distribution in vivo, suggesting that 
lower amounts of T4 and T3 were achieved in adipocytes in vivo in comparison to the in vitro 
study. Thyroid hormones have different effects in relation to PAI-1 gene expression in 
adipocytes in the intact rat (in vivo study) and in cultured adipocytes (in vitro study). Further 
studies are required to better elucidate the diverse in vivo and in vitro effects of thyroid 
hormone on adipocytes PAI-1 gene expression [156]. 
ASP - In a number of studies, ASP has been demonstrated to be increased in obesity, 
diabetes and cardiovascular disease [159-161]. Plasma ASP levels correlate positively with 
body mass index, as well as with plasma lipids. Study using culture of human adipocytes 
revealed increased secretion of chylomicrons induced by ASP [162]. There is evidence that 
circulating lipids also stimulate the expression of ASP after drinking large quantities of these 
nutrients [163]. There is no data available regarding the effect of thyroid hormones on ASP 
levels in obesity. 
RAS- Adipose tissue synthesizes and secretes the major components of RAS [164]. There is 
evidence for overactivation of adipose tissue RAS in obesity in rodents [165], and for a 
positive correlation between adipose tissue angiotensinogen levels and BMI in humans 
[166]. Also Ang II secretion from adipose tissue is increased in obese, but not lean, 
individuals [167]. Increased production of angiotensinogen with excess gain in white 
adipose tissue contributes to glucose intolerance development, insulin resistance, 
cardiovascular and renal diseases [76, 168, 169]. In addition, increased RAS activity 
contributes to inflammation in fat tissue [170]. The interaction of RAS with other adipokines 
also contributes to the development of metabolic syndrome. Ang II appears to stimulate 
leptin production by adipocytes [76]; which in turn, hyperleptinemia may further 
hyperactivity of RAS by stimulating renin release by the kidney. Ang II may also regulate 
negatively adipocyte production of adiponectin in both rodents and humans [171, 172]. 
Thyroid hormones are important regulators of cardiac and renal functions while RAS 
components act systemically and locally in individual organs also to control cardiovascular 
and renal functions. Several studies have implicated the systemic and local RAS in the 
mediation of functional and structural changes in cardiovascular and renal tissues due to 
abnormal thyroid hormone levels [173, 174]. Thyroid hormones also appear to stimulate 
expression and synthesis of RAS components [175-177]. 
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5. Thyroid hormone effects on adipokines in weight loss 
5.1. Leptin 
After weight loss, leptin levels decrease [178-180], as well TSH and T3 reduces to normal 
levels [92, 93, 112]. In starvation conditions, serum leptin levels decrease and thyroid 
hormones levels are quickly supressed, leading to a consequent reduction in energy 
expenditure [83].  
Varady et al. [181] studying severely obese women have suggested that a minimum weigh 
loss of 5% is required to improve adipokines profile, including the reduction of leptin levels. 
Not only a minimal weight loss is required but a maximal weigh loss beyond which further 
improvements in circulating adipokine levels are no longer observed has been suggested 
[179, 182]. The method or diet content by which weigh loss is achieved seems to be less 
important than the overall weight loss [179, 183]. 
As mentioned before, studies investigating the correlation between thyroid hormones and 
leptin levels present conflicting results. Luvizotto et al. showed that administration of 
physiologic levels of T3 increases leptin mRNA expression with no influence on body weight 
in calorie-restricted obese rats [108], while administration of supraphysiological T3 dose 
promotes weight loss and diminishes serum levels and gene expression of leptin [108] 
(Figure 3). Again, as Syed et al. [106] reported, the effects of thyroid hormones in leptin 
concentrations might be indirect trough the regulation of fat mass (Figure 4). The decline of 
TSH release and T3 concentrations associated with decrease in leptin levels after weight loss 
may contribute to the compensatory reductions of energy expenditure and catabolism that 
typically accompany weight loss [184]. 
As both thyroid hormones and leptin have major roles in energy balance and regulation of 
body weight, an interaction between these hormones could not be discarded to achieve or 
maintain weight loss but further studies are necessary to elucidate the relationship between 
leptin and thyroid hormones. 
5.2. Resistin 
Since obesity is considered a global epidemic and one of majors public health problem, 
affecting developed and developing countries [185, 186], and obese subjects may presente 
increased resistin levels [46], which can worse insulin resistance and inflammation [119], one 
of the most used strategies is the weight loss by reduction of caloric intake [187]. Caloric 
restriction affects the regulation of adipose tissue gene expression, normalizing the 
adipokines changes caused by obesity [10], while thyroid hormones play a central role in 
regulating adipose tissue metabolism [83], being related to body weight changes, thyroid 
hormones may therefore play a key role in the normalization of resistin in weight loss. 
Nogueiras et al. [130] show a decrease in resistin mRNA expression in epididymal adipose 
tissue of pregnant and nonpregnant rats that were subjected to food restriction. Kim et al. [188] 
showed that resistin mRNA levels were decreased during fasting, but increased considerably 
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when the animals were refed or after insulin infusion. T3 had no effect on resistin mRNA levels 
in adipose tissue of obese animals submitted to calorie restriction [189]. 
Normalization of circulating thyroid hormones was accompanied by a significant decrease 
in resistin concentrations [126]. Others showed that hyperthyroid patients exhibit a 
significant decrease in resistin levels compared with euthyroid individuals, and the 
normalization of circulating thyroid hormones was not accompanied by any significant 
change in resistin levels [127]. After adjusting the weight by the body mass index, the 
resistin levels in hyperthyroid patients were similar to euthyroid subjects [128] (Figure 4). 
The association between thyroid hormone and resistin in weight loss present conflicting 
data, requiring further studies to evaluate this relation. 
5.3. Adiponectin 
Negative correlation between obesity and circulanting adiponectin has been well accept, 
and adiponectin concentration increases concomitantly to weight loss [190].  
Experimental study on caloric restriction showed increased levels of circulating adiponectin 
[191]. Accordingly, Zhu et al. [194] showed that calorically restricted animals exhibited a 
significant increase in plasma adiponectin levels accompanied by significant decline in 
triglyceride levels, showing that adiponectin levels are inversely proportional to the degree 
of adiposity [192, 193].  
Thyroid hormones perform a central role in adipose tissue metabolism regulation [83], 
which produces the biologically active substances adipocytokines, or adipokines, that 
include adiponectin [127, 194], indeed thyroid hormones share some physiological actions 
with adiponectin, such as reduction of body fat by increased thermogenesis and lipid 
oxidation [194].  
The interaction between thyroid hormones and adiponectin concentration remains unclear. 
In humans, hyperthyroidism has been associated with both similar [128, 195] and elevated 
adiponectin concentrations [196], while experimental study with hyperthyroid rats found an 
increase in adiponectin serum concentration [133]. In agreement, some data shown that 
therapy to normalize hyperthyroidism significantly reduced circulating adiponectin levels 
[197]. In contrast Luvizotto et al. [189] show that thyroid hormone, at the doses of 5 and 25 
μg T3 / 100 g BW, diminishes adiponectin gene expression, suggesting that thyroid hormone 
modulates negatively adiponectin expression in calorie-restricted obese rats (Figure 4). 
5.4. Others adipokines 
TNF-α - The first information about the TNF-α biological effects indicated an involvement in 
insulin resistance, weight loss and anorexia. The increase in lipolysis result from TNF-α 
stimulus in hormone-sensitive lipase expression, leading to decreased activity of lipoprotein 
lipase. However, more recent investigations have revealed a molecular mechanism of 
weight loss on TNF-α levels, showing TNF-α expression is increased in obesity and 
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decreases with weight loss, thereby improving insulin sensitivity [135, 198]. After weight 
loss there is a decrease of macrophages number in adipose tissue [199], this can lead to 
decreased TNF-α levels, since both adipose tissue and macrophages produce this cytokine. 
There are few studies correlating the thyroid status with TNF-α levels in weight loss. 
Patients with HIV tend to lose weight and in some cases it is observed a decrease in T3 levels 
accompanied by increased TNF-α levels, when these individuals are compared to patients 
with HIV with normal T3 levels. These results corroborate to other study linking the sick 
euthyroid syndrome to high TNF-α levels in cachectic patients with HIV [200].  
 
Figure 4. Thyroid hormone may modulate adipokines concentration by regulating adipose tissue 
metabolism by, i.e., increasing lipid oxidation leading to body fat decreased. The exact influence of 
thyroid hormone on adipokines remains unclear.  
IL-6 - IL-6 levels decrease with weight loss [140-142]. The intracerebroventricular 
administration of this cytokine can decrease body fat [201]. Association studies between 
thyroid hormones and IL-6 in weight loss are scarce, but studies in critically patients 
demonstrated a direct association between decreased T3 levels and high IL-6 plasma levels, 
demonstrating that approximately 28% of T3 fall could be directly related to increased IL-6 
[202]. In another study, of 270 patients admitted to intensive care unit, serum T3, T4 and IL-6 
were measured and again was observed a negative correlation between T3 and T4 levels and 
IL-6 levels, demonstrating that this cytokine could be an important factor associated with 
decreased circulating thyroid hormones levels [203].  
MCP-1 - Chronic inflammation associated with obesity exists in dogs, and it is evident that 
weight loss decreases this inflammation as observed by decreasing MCP-1 after weight loss 
[204]. In agreement, Kanda et al. [205] demonstrated that MCP-1 deficient mice have 
reduced adipose tissue macrophage infiltration. Few studies correlate weight loss and MCP-
1 levels, and no data was found regarding weight loss, MCP-1 and thyroid association. 
PAI-1 - Weight loss secondary to calorie restriction is associated with reduced PAI-1 activity 
in adults [206, 207]. However, in children no significant change in PAI-1 levels was observed 
in 43 obese children after a physical training program [208]. This may be explain by the 
increase in fibrinolytic activity due to a decrease in PAI-1 antigen levels in obese children 
after weight loss, and a significant positive correlation was observed between variations in 
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body mass index and variations in PAI-1 levels. Moreover, the largest decrease in PAI-1 
levels was observed in the obese children with the highest previous PAI-1 levels [209]. 
Weight loss induced by a low calorie diet causes a decrease in plasma PAI-1 levels especially 
among obese individuals [210, 211], and these increase once again if weight is regained 
[212]. Surgically removing fat confers the same beneficial effect [212]. Antidiabetic drugs 
such as thiazolidinediones, metformin, and AT1-receptor antagonists reduce adipose PAI-1 
expression [211].  Interestingly, waist-to-hip ratio, a reflection of central fat accumulation, 
has been found in women to be the only independent predictor of circulating PAI-1 activity 
[213]. In individuals subjected to a calorie restricted diet, PAI-1 levels were more closely 
related to changes in the central fat deposit than in the subcutaneous fat deposit [214]. Thus, 
the visceral fat deposit may be importante for the occurrence of increased plasma PAI-1 
levels. There is few data available regarding the thyroid hormones and PAI-1. Studies have 
been focused on serum measurements, in severe hypothyroidism was found decreased PAI-
1 levels [215], while in hyperthyroidism some studies show increased [113, 216, 217], other 
decreased [83, 218] as well as unaffected PAI-1 levels [219, 220].  
RAS - Studies with RAS manipulation (deletion) showed that function loss in any single 
component of RAS tested so far, provides protection from diet-induced obesity and insulin 
resistance [221-224]. Therefore, RAS seems to play a role in obesity development; however 
systemic RAS overactivation via gene overexpression or chronic Ang II infusion also induces 
insulin resistance, but not necessarily obesity [225]. Weight loss in humans results in decreases 
in circulating components of the RAS [226]. In fact, Engeli et al. [226] suggest that a 5% 
reduction in body fat mass can reduce meaningfully the RAS in plasma and adipose tissue, 
which may contribute to reduce blood pressure. Genetic polymorphisms of RAS may also play 
a role in response to weight loss in obese individuals [227]. Decrease of RAS leads to 
improvement in insulin sensitivity, blood pressure, and renal function. As RAS interacts with 
others adipokines, reduction in RAS concentrations followed weight loss may also contributes 
to improvement of other adipokines levels and, consequently, improve other metabolic 
disorders [226, 228]. As mentioned, thyroid hormones appear to stimulate expression and 
synthesis of RAS components [175-177]. However, precise interaction between thyroid 
hormones and RAS components in weight loss process are scarce in the literature. 
Literature on newer adipokines and thyroid disorders is scarce. No data on ASP and weight 
loss is available and no data on these adipokines and thyroid hormone have been published 
so far. Future research studying these associations is awaited. 
6. The use of TRβ analogues 
Thyroid hormone analogues, termed thyromimetics, are molecules with activate signaling 
pathway property similar to thyroid hormones, sometimes with tissue specificity or by 
activating a singular pathway stimulated by thyroid hormones, other with less effect, but 
even with a way close to thyroid hormones. The thyromimetics have a great pharmaceutical 
potential since they present certain specificity as intracellular signaling that stimulate and 
thus may have a tissue specific action. However, only the past 20 years, with increasing 
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resolution of three-dimensional models, docking experiments and crystallography models 
the specificity of thyromimetics has been revealed. 
Thyroid hormone is one of the most responsible for metabolism controlling and cell oxygen 
consumption, affecting growth, cell differentiation and homeostasis control [229]. The 
thyroid hormone also has specific functions depending on tissue: in liver, controlling lipid 
metabolism [230-232]; in heart, regulating the calcium handling and the heart rate [233]. As 
for lipid deposits, the thyroid hormone acts in brown adipose tissue by controlling heating 
and adaptive thermogenesis during rest [234]. Under high hormone levels conditions in the 
organism, such as hyperthyroidism, there is an increase in metabolic rate with consequent 
weight loss and decrease cholesterol serum levels, desirable conditions for metabolic 
diseases treatment such as obesity [235] and hyperlipidemia [230-232]. In this context, the 
possible specificity through thyroid homone analogues may lead to desirable effects on 
adipokines release control and obesity, without the undesirable symptoms on heart or on 
TSH release. 
Thyromimetics can be seen as thyroid hormone derivative or its metabolites derivative. 
Studies on the direct influence of these analogues on adipokines levels are scarce, but the 
tissue selectivity shown may be interesting in the study of non thyroid diseases, mainly 
involving the lipid rate control in adipose tissue and decreased cholesterol by the liver. This 
selectivity in many cases is related to action pathway stimulate by thyromimetics. Some of 
them may have actions in liver and adipose tissue through its selective binding to TR-β1, 
while not lead to effects such as tachycardia since there is no selectivity for the TR-α1 (most 
expressed isoform in the heart). Thus we can highlight some known thyromimetics and 
some details of their actions. 
The first developed analogue, in the mid-1980s, was 3,5-dibromo-3-pyridazinone-L-
thyronine (L-94901) present 50% of binding T3 to TRs in liver, and only 1.3% effective for 
cardiac TRs [236, 237]. L-94901 showed an increase of oxygen overall consumption and a 
reduction in cholesterol serum levels in animal models submitted to low dose, sufficient to 
prevent cardiotoxic effects, however, also led to lower TSH, T4 and T3 plasma levels [236]. 
An analogue selectivity-related to TR-β1 is 3,5-Dichloro-4-[(4-hydroxy-3-isopropylphenoxy)-
phenyl] acetic acid (KB-141), with 10-fold greater ability to reduce the cholesterol rate than 
increase heart rate [238, 239], stimulating metabolic rate and oxygen consumption [240]. 
Eprotirome (KB2115) is a thyroid hormone analogue that has a low uptake by non-hepatic 
tissues. It has preferential selectivity for the TRβ, leading to decreased total cholesterol, LDL 
and apolipoprotein B levels without apparent side-effects. It showed good results in 
hypercholesterolemia treatment and associated with statin was effective in reducing 
atherogenic lipoproteins levels without extra-hepatics effects of thyroid hormone [241]. 
One of the most widely studied thyroid hormone analogues is 3,5-dimethyl-4-[(4'-hydroxy-
3'-isopropylbenzyl)-phenoxy] acetic acid (CG-1), with selectivity for TRβ 10-fold greater 
than for TR-α. Hypercholesterolemic rats models treated with GC-1 showed decrease in 
cholesterol, LDL and triglyceride serum levels, without significantly altering heart function 
or regulated-thyroid hormone gene expression as MHC-HT and α, β-MHC and SERCA2 
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[242]. The same results were observed with KB-141 use, but with a subtle increase in heart 
rate. Contributing to cholesterol serum levels reduction by GC-1 is the increased SR-BI 
expression, a receptor that promotes cholesterol uptake in the liver, stimulating the bile 
acids production [243]. Deleterious effects absence of GC-1 on cardiac structure and function 
[244], skeletal muscle and bone mass [245] suggests that GC-1 has potential therapeutic use 
for metabolic disorders such as obesity and hyperlipidemia [246]. 
Started studies during the mid-1990s, N-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylphenoxy)-
phenyl] oxamic acid (CGS-23425) was a potent ability to decrease cholesterol in rats and 
dogs at dose 25 times higher than the minimum for producing lipid lowering effects [247]. 
In hypercholesterolemic rats, CGS-23425 had the desired effects of decreasing serum LDL 
and increased apoA1, with a corresponding increase in apoA1 gene transcription by TR-β1 
selectively [248]. 
A thyroid hormone analogue currently in phase II clinical trial is the 3.5-
diiodothyropropionic acid (DITPA), with affinity equivalent between TR-α1 and β1 but with 
100 times less affinity than T3 [249]. In hypothyroid rats, DITPA improved cardiac 
performance with half the chronotropic effect and less metabolic stimulation than 
levothyroxine [250]. In normal volunteers, DITPA does not affect the heart rate or blood 
pressure, while the serum cholesterol and triglycerides were significantly decreased [251]. 
Observations have shown that DIPTA exerts its action by stimulating nongenomic pathways 
stimulated by T3 as the αVβ3 integrin receptor, activating the MAPK cascade and causing 
similar effects to those seen with GC-1, leading to angiogenesis, indicating that some cardiac 
effects may be caused by nongenomic pathway activation [252]. 
Although there are few studies on thyromimetics and adipokines, studies on obesity and 
lipid lowering show interesting results. Other compounds have been studied as thyroid 
hormone natural metabolic intermediates: 3-iodothyronamine (T1AM) showed effects on 
cardiac output, heart hate and decreased body temperature with neuroprotective action; 
Diiodothyronine-3.5 (T2) with effects such as increased lipid peroxidation and fatty acids 
oxidation, among others; 3,3 ', 5'-triiodothyronine (rT3) able to initiate actin polymerization; 
triiodothyroacetic acid (Triac) that increases the metabolic rate and thermogenesis, and one 
of the few identified analogues able to increase leptin secretion [246]. Like thyromimetics, 
these natural metabolites, collectively, show body weight and fat mass reduction, while 
thyromimetics are more specific to reduce cholesterol serum levels, but both have effects 
saving cardiac activity. However, before they are used in large scale, attention should be 
paid to non-selectivity presented by natural metabolites, and for TSH suppression showed 
by thyromimetics, which may lead to undesirable tissue hypothyroidism. Thus, the tissue 
specificity and selectivity for TR brings a good perspective for thyromimetics, however there 
is still a long way from its use as therapeutic agent. 
7. Final considerations 
Adipose tissue produces a wide range of biological active substances, named adipokines, 
involved in glucose metabolism, lipid metabolism, inflammation, coagulation, blood 
pressure, and feeding behavior, thus affecting metabolism and function of many organs and 
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tissues including muscle, liver, vasculature, and brain. Obesity cause imbalance in the 
adipokines production, while the weight loss are able to normalize these changes. In obese, 
the stabilization of weight loss even in calorie restricted diet has been attributed to the 
decrease in serum T3 concentrations, leading to a reduction in metabolic rate. Because of 
this, and despite not being accepted as an obesity treatment, the administration of thyroid 
hormones, in isolation or in association with hypocaloric diets, is sometimes used illicitly. 
The thyroid hormones regulate the energetic balance and act on the adipokines, regulating 
several genes in adipose tissue. However, the available data on the effects of thyroid 
hormone on adipokines in obesity or weight loss are conflicting. A clear association has not 
yet been established between in obesity and calorie restriction in obesity and the effect of 
thyroid hormone on adipokines, requiring further studies. Despite studies of TRβ analogs 
show good results, the direct influence of these analogues on adipokines levels are scarce. 
More research is needed to fully elucidate the exact mechanism of thyroid hormone and its 
analogues on adipokines in obesity and weight loss. 
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